At the news
? MIXEDIMPACT 5/10 PRESS-RELEASE filed Mar 30, 2026 at 06:53 ET
Neumora Therapeutics reported Q4 and full-year 2025 financial results with reduced R&D and G&A expenses, resulting in a narrower net loss compared to the prior year. The company highlighted clinical progress across its pipeline, including new Phase 1b data for NMRA-511 in Alzheimer’s agitation, full enrollment in the KOASTAL-2 and -3 trials for navacaprant, and advancement of NMRA-898 as the lead M4 program in schizophrenia. With $182.5 million in cash, Neumora expects to fund operations into Q3 2027.
- Neumora reported $182.5 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
- R&D expenses decreased to $176.1 million in 2025 from $200.9 million in 2024, primarily due to reduced navacaprant-related costs.
- Net loss for full-year 2025 was $236.9 million, down slightly from $243.8 million in 2024.
- NMRA-511 showed a Cohen’s d effect size of 0.34 on CMAI total score and 0.51 on aggression sub-factor in a pre-specified Alzheimer’s agitation population.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access